BiotechTube
Caliway Biopharmaceuticals

Caliway Biopharmaceuticals

6919.TW
Taiwan

Caliway Biopharmaceuticals is dedicated to developing innovative small-molecule drugs for aesthetic medicine and inflammatory diseases. Its core technology focuses on inducing adipocyte apoptosis (programmed cell death) without surgery. The company has advanced its lead candidate, CBL-514, into mid-stage clinical trials and achieved a significant market valuation following its public listing, positioning it as a key player in the non-invasive aesthetic therapeutics space.

caliway.com.tw

6919.TW · Stock Price

USD 92.80+3.70 (+4.15%)
Market Cap: $4.5B

Historical price data

AI Company Overview

Caliway Biopharmaceuticals is dedicated to developing innovative small-molecule drugs for aesthetic medicine and inflammatory diseases. Its core technology focuses on inducing adipocyte apoptosis (programmed cell death) without surgery. The company has advanced its lead candidate, CBL-514, into mid-stage clinical trials and achieved a significant market valuation following its public listing, positioning it as a key player in the non-invasive aesthetic therapeutics space.

Aesthetic MedicineMetabolic DisordersInflammatory Diseases

Technology Platform

Proprietary platform of small-molecule compounds designed to induce caspase-mediated apoptosis (programmed cell death) in adipocytes (fat cells) for non-invasive treatment of localized fat and related disorders.

Pipeline

12
12 drugs in pipeline1 in Phase 3
DrugIndicationStageWatch
CBL-514 InjectionSubcutaneous FatPhase 3
CBL-514Subcutaneous FatPhase 2
CBL-514 InjectionSubcutaneous FatPhase 2
CBL-514 injectionCellulitePhase 2
CBL-514 InjectionSubcutaneous FatPhase 2

Funding History

3
Total raised:$135M
IPO$60MJan 30, 2024
Series B$50MDec 15, 2022
Series A$25MJun 15, 2021

Opportunities

CBL-514 has the potential to create a new drug-based market segment in the multi-billion dollar non-invasive aesthetic industry.
Successful development for therapeutic indications like Dercum's disease could provide orphan drug designations, expedited pathways, and premium pricing.
The company's public listing provides a platform for future capital raises and potential visibility for global partnerships.

Risk Factors

High dependency on the success of a single lead candidate (CBL-514) across multiple trials.
Faces competition from entrenched medical device technologies with strong physician loyalty.
Must demonstrate a compelling efficacy and safety advantage to change clinical practice.
Regulatory approval is not guaranteed.

Competitive Landscape

Primary competitors are medical device companies offering non-invasive fat reduction technologies like Allergan's CoolSculpting®. Caliway differentiates by offering a pharmacologic, injectable solution that may allow for more precise contouring and predictable outcomes compared to energy-based devices. Its main challenge is proving clinical superiority and establishing a new treatment paradigm.